M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 12.04 PLN 1.35% Market Closed
Market Cap: 194.6m PLN
Have any thoughts about
Mabion SA?
Write Note

Relative Value

The Relative Value of one MAB stock under the Base Case scenario is 13.91 PLN. Compared to the current market price of 12.04 PLN, Mabion SA is Undervalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MAB Relative Value
Base Case
13.91 PLN
Undervaluation 13%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
65
vs Industry
80
Median 3Y
2
Median 5Y
1.8
Industry
7.7
Forward
2.2
vs History
11
vs Industry
11
Median 3Y
7.8
Median 5Y
6.2
Industry
22.7
Forward
-238.4
vs History
26
vs Industry
2
Median 3Y
3.5
Median 5Y
-8.5
Industry
21.6
vs History
vs Industry
8
Median 3Y
-4.6
Median 5Y
-11.6
Industry
25.2
vs History
69
vs Industry
43
Median 3Y
3.1
Median 5Y
2.5
Industry
2.5
vs History
65
vs Industry
73
Median 3Y
1.8
Median 5Y
1.5
Industry
7.7
Forward
1.7
vs History
65
vs Industry
70
Median 3Y
2.8
Median 5Y
2.2
Industry
9
vs History
41
vs Industry
13
Median 3Y
3.9
Median 5Y
2.5
Industry
4.2
Forward
8.5
vs History
34
vs Industry
11
Median 3Y
4.4
Median 5Y
2.8
Industry
4.1
Forward
10.2
vs History
28
vs Industry
2
Median 3Y
2.7
Median 5Y
-8.5
Industry
5.7
vs History
12
vs Industry
9
Median 3Y
-4
Median 5Y
-6.3
Industry
3.6
vs History
98
vs Industry
52
Median 3Y
1.9
Median 5Y
3.5
Industry
4.6

Multiples Across Competitors

MAB Competitors Multiples
Mabion SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Mabion SA
WSE:MAB
194.6m PLN 1.8 19 3.8 4.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
PL
M
Mabion SA
WSE:MAB
Average P/E: 176.7
19
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
PL
M
Mabion SA
WSE:MAB
Average EV/EBITDA: 15.3
3.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
PL
M
Mabion SA
WSE:MAB
Average EV/EBIT: 20
4.9
-82%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top